ASTRAZENECA

📅 Upcoming

🕒 Recent(90d)

News

• BMS welcomes new multiple myeloma drug as generics batter current portfolio
  The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…
  biospace · 2h ago
• Biotech initiatives pick up as more regions race to become hubs
  New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
  biopharma_dive · 3h ago
• New Taiho, Cullinan data heats up lung cancer drug battle
  The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
  biopharma_dive · 22h ago
• Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
  Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
  biospace · 23h ago
• Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
  Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…
  fiercebiotech · 1d ago
• Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
  As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
  fiercebiotech · 1d ago
• BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
  BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.
  biospace · 2d ago
• Vaderis hauls in $152M to test an AKT-targeting drug
  The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
  biopharma_dive · 3d ago
• Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
  Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.
  fiercebiotech · 3d ago
• AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
  News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
  biospace · 3d ago